TD Asset Management Inc Acquires 45,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Key Points

• TD Asset Management Inc increased its stake in Ultragenyx Pharmaceutical Inc. by 48.1%, purchasing an additional 45,000 shares and now owning approximately 138,484 shares valued at around $5 million.
• Ultragenyx Pharmaceutical reported a 28.0% year-over-year revenue increase, but its earnings per share of ($1.57) missed analysts' expectations, leading to a negative net margin of 93.04%.
• Analysts have mixed ratings on Ultragenyx Pharmaceutical, with an average target price of $82.57 and several firms giving it a "buy" rating, indicating potential upside despite recent performance challenges.

TD Asset Management Inc raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 48.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 138,484 shares of the biopharmaceutical company's stock after acquiring an additional 45,000 shares during the quarter. TD Asset Management Inc owned about 0.15% of Ultragenyx Pharmaceutical worth $5,015,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in RARE. GAMMA Investing LLC boosted its holdings in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $35,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $57,000. GF Fund Management CO. LTD. bought a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $82,000. Finally, Quarry LP acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $84,000. 97.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Guggenheim reiterated a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Morgan Stanley cut their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, July 14th. HC Wainwright upgraded shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective on the stock in a research note on Monday, July 28th. Wedbush cut their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. Finally, William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 price target on the stock. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and a consensus price target of $82.17.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares in the company, valued at $573,712.16. This represents a 13.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 5.9%

NASDAQ:RARE traded down $1.70 during mid-day trading on Wednesday, hitting $27.22. The company's stock had a trading volume of 1,731,287 shares, compared to its average volume of 1,278,179. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of -4.62 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $60.37. The stock has a fifty day moving average of $33.72 and a 200-day moving average of $37.02.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. The business had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. Ultragenyx Pharmaceutical's revenue was up 13.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.52) EPS. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.